^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CBA-1205

    i
    Other names: CBA-1205, LIV-1205
    Associations

    News

    Trials
    Company:
    Chiome Biosci
    Drug class:
    DLK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer (clinicaltrials.gov)
    P1, N=66, Recruiting, Chiome Bioscience Inc. | N=50 --> 66 | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CBA-1205
    11ms
    A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors. (PubMed, Cancer Sci)
    CBA-1205 was well tolerated, showing no severe toxicity in patients with advanced or recurrent solid tumors. The favorable safety profile and indications of potential activity support further investigation in Parts 2 and 3 of this Phase I study to evaluate the safety, tolerability, and preliminary efficacy of CBA-1205.
    P1 data • Journal
    |
    DLK1 (Delta Like Non-Canonical Notch Ligand 1)
    |
    DLK1 expression
    |
    CBA-1205
    1year
    A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients with Advanced Solid Tumors and Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1, N=50, Recruiting, Chiome Bioscience Inc.
    New P1 trial
    |
    CBA-1205
    over2years
    Synergistic and long-lasing anti-tumor efficacy of CBA-1205, a novel glycoengineered humanized antibody targeting DLK-1, in combination with lenvatinib in human HCC xenograft models. (AACR 2023)
    Similar results were obtained with CBA-1205 at 1 mg/kg dosage in combination with lenvatinib at 10 mg/kg dosage in HepG2 xenograft model. In conclusion, we demonstrated synergistic and long-lasting anti-tumor efficacy of CBA-1205 in combination with lenvatinib in two different HCC pre-clinical models suggesting that the combination could be a new treatment option for unresectable advanced HCC.
    Preclinical • Combination therapy
    |
    EGF (Epidermal growth factor)
    |
    Lenvima (lenvatinib) • CBA-1205